{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Derived from dosimetry estimates coupled with the absorbed dose to normal organs based on the administered activity of 90Y.","groups":[{"description":"Patients receive indium-111 anti-CD45 monoclonal antibody BC8 IV on day -28 and (if necessary) day -21. Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV on day -28, -14, and -13. Patients then undergo autologous peripheral blood stem cell transplantation on day 0.\n\nindium In 111 anti-CD45 monoclonal antibody BC8: Given IV\n\nyttrium Y 90 anti-CD45 monoclonal antibody BC8: Given IV\n\nperipheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell transplant","id":"OG000","title":"Treatment (Yttrium-90 Anti-CD45 Monoclonal Antibody BC8)"}],"populationDescription":"This outcome measure was not done. Only two patients were enrolled before the study was closed early. Tumor to normal organ ratios was not determined due to small sample size.","reportingStatus":"POSTED","timeFrame":"Up to 6 years","title":"Tumor to Normal Organ Ratios","type":"SECONDARY"}